ERNA — Ernexa Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 748592 ·
Last close
$1.63
Market Cap
$2.66M
52W High
$38.00
52W Low
$1.57
ADV30
46,270
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -2,990,000 | -2,941,000 | 7,104,000 | 5,575,000 | 2,753,000 |
| Jun 2026 | 0 | — | -4,104,000 | -4,009,000 | 6,315,000 | 5,028,000 | 3,115,000 |
| Mar 2026 | 0 | 0 | -3,546,000 | -5,506,000 | 10,543,000 | 9,177,000 | 3,684,000 |
| Dec 2025 | 0 | 0 | -2,094,000 | -1,502,000 | 5,834,000 | 1,884,000 | 3,433,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,836,000
Investing CF
$-42,000
Financing CF
$9,591,000
CapEx
$-20,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-29.29
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-255,159,000
Inventory
—
Receivables
$83,000
ST Investments
—
EBIT TTM
$-16,520,000
Pretax Income TTM
$-12,353,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,319,000 | -14,084,000 | 5,830,000 | 3,433,000 | 2,401,000 | -7,017,000 |
| Dec 2024 | 582,000 | -17,250,000 | -44,539,000 | 5,269,000 | 3,568,000 | 1,701,000 | -15,836,000 |
| Dec 2023 | 68,000 | -20,675,000 | -21,668,000 | 49,132,000 | 46,899,000 | 2,233,000 | -20,408,000 |
| Dec 2022 | 0 | -26,947,000 | -24,579,000 | 22,279,000 | 10,172,000 | 12,107,000 | -20,976,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-12,258,000
OpCashFlow TTM
—
Assets (Latest)
$6,315,000
Forward EPS
$-9.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIXT | BIOXYTRAN, INC | $2.66M | $0.02 | — |
| NXTS | Nexentis Technologies Inc. | $2.65M | $1.82 | — |
| MBIO | MUSTANG BIO, INC. | $2.63M | $0.39 | — |
| EOCN | EoCene Ltd. | $2.63M | $2.46 | — |
| PPBT | PURPLE BIOTECH LTD. | $2.78M | $1.71 | — |
News headlines (Yahoo Finance, 1h cache)
Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
2026-10-22 12:53 · Yahoo
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
2026-10-12 20:05 · Yahoo
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
2026-10-06 12:55 · Yahoo
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
2026-10-01 13:20 · Yahoo
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
2026-09-30 12:32 · Yahoo
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
2026-09-29 13:15 · Yahoo
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
2026-09-17 12:42 · Yahoo
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-14 13:05 · Yahoo
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-27 13:01 · Yahoo
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
2026-07-24 13:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.